Mechanisms of 3-Hydroxyl 3-Methylglutaryl CoA Reductase in Alzheimer’s Disease
International Journal of Molecular Sciences · 22.12.2023 · 25 (1) · 170
DOI: 10.3390/ijms25010170 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 22.12.2023. Verfasst von Xun Zhou und 5 weiteren Autor:innen. Beteiligte Einrichtung: Science and Technology Innovation Center, Guangzhou University of Chinese Medicine, Guangzhou 510405, China. Hauptthemen laut MEDLINE: Alzheimer Disease, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Neurodegenerative Diseases. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 136 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Guangdong Province.
Themen: Demenz
Abstract (Originalsprache)
Alzheimer’s disease (AD) is the most common neurodegenerative disease worldwide and has a high incidence in the elderly. Unfortunately, there is no effective therapy for AD owing to its complicated pathogenesis. However, the development of lipid-lowering anti-inflammatory drugs has heralded a new era in the treatment of Alzheimer’s disease. Several studies in recent years have shown that lipid metabolic dysregulation and neuroinflammation are associated with the pathogenesis of AD. 3-Hydroxyl 3-methylglutaryl CoA reductase (HMGCR) is a rate-limiting enzyme in cholesterol synthesis that plays a key role in cholesterol metabolism. HMGCR inhibitors, known as statins, have changed from being solely lipid-lowering agents to neuroprotective compounds because of their effects on lipid levels and inflammation. In this review, we first summarize the main regulatory mechanism of HMGCR affecting cholesterol biosynthesis. We also discuss the pathogenesis of AD induced by HMGCR, including disordered lipid metabolism, oxidative stress, inflammation, microglial proliferation, and amyloid-β (Aβ) deposition. Subsequently, we explain the possibility of HMGCR as a potential target for AD treatment. Statins-based AD treatment is an ascent field and currently quite controversial; therefore, we also elaborate on the current application prospects and limitations of statins in AD treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Science and Technology Innovation Center, Guangzhou University of Chinese Medicine, Guangzhou 510405, China.
- Department of Endocrinology, The Fourth Clinical Medical College of Guangzhou University of Chinese Medicine, Shenzhen 518033, China.
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Guangdong Province
Zitieren
APA
Zhou, X., Wu, X., Wang, R., Han, L., Li, H., & Zhao, W. (2023). Mechanisms of 3-Hydroxyl 3-Methylglutaryl CoA Reductase in Alzheimer’s Disease. International Journal of Molecular Sciences, 25(1), 170. https://doi.org/10.3390/ijms25010170
Vancouver
Zhou X, Wu X, Wang R, Han L, Li H, Zhao W. Mechanisms of 3-Hydroxyl 3-Methylglutaryl CoA Reductase in Alzheimer’s Disease. International Journal of Molecular Sciences. 2023;25(1):170. doi:10.3390/ijms25010170
BibTeX
@article{Zhou2023,
author = {Zhou, Xun and Wu, Xiaolang and Wang, Rui and Han, Lu and Li, Huilin and Zhao, Wei},
title = {Mechanisms of 3-Hydroxyl 3-Methylglutaryl CoA Reductase in Alzheimer’s Disease},
journal = {International Journal of Molecular Sciences},
year = {2023},
volume = {25},
number = {1},
pages = {170},
doi = {10.3390/ijms25010170}
}
EUVIMED